Welcome to our dedicated page for Protagonist Ther SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protagonist Therapeutics, Inc. (NASDAQ: PTGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to official information the company submits to the U.S. Securities and Exchange Commission. Protagonist identifies itself in these filings as a biopharmaceutical company with principal executive offices in Newark, California, and uses them to report financial results, corporate updates, and other material events.
Among the key documents available are Form 8-K current reports, which Protagonist files to announce specific developments. Recent 8-K filings referenced in company communications include notices of quarterly financial results and corporate updates, as well as the availability of an updated corporate presentation. These filings typically incorporate press releases as exhibits, providing details on clinical milestones for icotrokinra and rusfertide, collaboration arrangements with Johnson & Johnson and Takeda, and financial metrics.
Investors can also use Protagonist’s SEC filings to follow governance and shareholder matters. For example, a Form 8-K describing the 2025 Annual Meeting of Stockholders outlines the election of directors, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. Such disclosures help readers understand how the company’s board composition and oversight framework are presented to shareholders.
On Stock Titan, these filings are paired with AI-powered summaries that explain the main points of lengthy documents in plain language. When Protagonist files quarterly or annual reports, investors can quickly review how the company characterizes its business, pipeline, collaborations, and risks without reading every page. For current reports on clinical or regulatory milestones, AI summaries highlight the aspects most relevant to PTGX, such as references to icotrokinra’s NDA, rusfertide’s Phase 3 data and NDA submission, or updates to the company’s corporate presentation.
In addition, users can monitor real-time updates from EDGAR so that new Protagonist filings appear promptly as they are posted. Where applicable, Stock Titan also surfaces insider transaction reports (Form 4) and proxy materials, giving a consolidated view of trading by officers and directors, compensation-related votes, and other governance topics. Together, these tools help investors interpret Protagonist’s regulatory record and connect formal disclosures to the company’s clinical and collaboration narrative.
Protagonist Therapeutics, Inc. reported that it has made an updated corporate presentation available as of January 12, 2026. The presentation is provided as Exhibit 99.1 to a current report on Form 8-K under Regulation FD, which is intended to share information broadly with the market. The company notes that this information, including the exhibit, is being furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.
Protagonist Therapeutics, Inc. (PTGX) reported an insider equity change involving its President and CEO, who is also a director. On 11/21/2025, the reporting person made a bona fide gift of 440 shares of common stock, identified with transaction code "G" for a gift. The filing notes that the gift was made to the reporting person’s grandchild.
Following this gift transaction, the reporting person beneficially owns 519,543 shares of PTGX common stock, held directly. This Form 4 reflects a personal, non-sale transfer and does not describe any purchase or sale of shares on the market.
Protagonist Therapeutics, Inc. (PTGX) reported an insider tax-related sale by its Chief Medical Officer. On 11/17/2025, Chief Medical Officer Arturo Molina reported selling 2,712 shares of common stock at a price of $84.77 per share. The sale was made to cover tax withholding obligations incurred when restricted stock units settled, rather than as an open-market discretionary sale.
Following this transaction, Arturo Molina beneficially owned 81,180 shares of Protagonist Therapeutics common stock in direct form. The filing was made by a single reporting person and does not list any derivative securities transactions.
Protagonist Therapeutics (PTGX) filed its Q3 2025 10‑Q, highlighting steady collaboration revenue and strong liquidity. License and collaboration revenue was $4.7 million for the quarter and $38.6 million year-to-date, primarily from the Takeda rusfertide agreement. The company reported a net loss of $39.3 million for Q3 and $85.8 million for the first nine months, reflecting ongoing Phase 3 development and operating costs.
Cash, cash equivalents, and marketable securities totaled $678.8 million as of September 30, 2025, supported by prior upfronts and a $25.0 million milestone from Takeda received in September 2025. Deferred revenue was $17.0 million, to be recognized as development services conclude. R&D expense was $40.0 million and G&A was $11.1 million in Q3.
Operationally, JNJ submitted an NDA to the FDA in July 2025 and an MAA to the EMA in September 2025 for icotrokinra in plaque psoriasis. Rusfertide for polycythemia vera received FDA Breakthrough Therapy designation in August 2025, with Phase 3 VERIFY positive topline results announced in March 2025. As of October 29, 2025, 62,515,666 common shares were outstanding.
Protagonist Therapeutics (PTGX) filed a current report announcing it has reported financial results for the quarter ended September 30, 2025. The company furnished a press release titled “Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update” as Exhibit 99.1.
The report states the information, including the exhibit, is furnished and not deemed “filed” under the Exchange Act and will not be incorporated by reference into other SEC filings. The filing lists PTGX common stock on The Nasdaq Stock Market and is signed by Chief Financial Officer Asif Ali.
Protagonist Therapeutics (PTGX)
Sales included 4,000 shares at $69.25 and 8,000 shares at a $87.81 weighted average, with individual trades ranging from $86.71 to $88.00. Following these transactions, he directly holds 5,130 shares. The exercised options were fully vested and were set to expire on 05/28/2028.
Protagonist Therapeutics, Inc. (PTGX) reported an insider notice to sell 12,000 common shares via Morgan Stanley Smith Barney on
Two prior 10b5-1 sales attributed to William Waddill are disclosed:
Protagonist Therapeutics director William D. Waddill sold 4,000 shares of Protagonist Therapeutics, Inc. (PTGX) common stock on 09/22/2025 at a price of $64.25 per share, leaving him with 5,130 shares beneficially owned following the transaction. The sale was executed under a Rule 10b5-1 trading plan that the reporting person adopted on November 10, 2023. The Form 4 was signed on behalf of Mr. Waddill by an attorney-in-fact on 09/24/2025. The filing reports the transaction as a non-derivative disposition by a director and indicates the Form was filed by one reporting person.
Form 144 notice for Protagonist Therapeutics, Inc. (PTGX) reports a proposed sale of 4,000 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $248,800 and an approximate sale date of 09/22/2025 on NASDAQ. The filer acquired the shares on 05/03/2022 via previously exercised stock options and paid cash. The filing also discloses a 10b5-1 sale by the same person of 4,000 shares on 08/27/2025 for gross proceeds of $237,000. The notice includes the seller’s representation about absence of undisclosed material adverse information.
Dinesh V. Patel, Ph.D., President and CEO and director of Protagonist Therapeutics, Inc. (PTGX), reported a change in beneficial ownership on Form 4. The filing discloses a transaction dated 09/16/2025 in which Dr. Patel made a bona fide gift of 620 shares of the issuer's common stock to his son at a reported price of $0 (coded G). After the reported transaction, Dr. Patel beneficially owned 519,983 shares, held directly. The Form 4 was signed on 09/18/2025 by Matthew Gosling as attorney-in-fact for Dr. Patel.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
